171 related articles for article (PubMed ID: 37754507)
21. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
[TBL] [Abstract][Full Text] [Related]
24. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
25. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gershenson DM; Sun CC; Westin SN; Eyada M; Cobb LP; Nathan LC; Sood AK; Malpica A; Hillman RT; Wong KK
Gynecol Oncol; 2022 Jun; 165(3):560-567. PubMed ID: 35606067
[TBL] [Abstract][Full Text] [Related]
26. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
[TBL] [Abstract][Full Text] [Related]
27. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
28. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract][Full Text] [Related]
29. Outcome and prognostic factors of low‑grade serous ovarian cancer: An observational retrospective study.
Alhusaini H; Badran A; Al Juhani A; Alshamsan B; Alsagaih Y; Alqayidi AA; Sheikh A; Elhassan T; Maghfoor I; Elshentenawy A; Elshenawy MA
Mol Clin Oncol; 2024 Jul; 21(1):47. PubMed ID: 38872951
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
31. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S
Gynecol Oncol; 2023 May; 172():72-77. PubMed ID: 36965291
[TBL] [Abstract][Full Text] [Related]
32. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD
Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021
[TBL] [Abstract][Full Text] [Related]
33. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Grabowski JP; Harter P; Heitz F; Pujade-Lauraine E; Reuss A; Kristensen G; Ray-Coquard I; Heitz J; Traut A; Pfisterer J; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):457-62. PubMed ID: 26807488
[TBL] [Abstract][Full Text] [Related]
34. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
Brown JV; Micha JP; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2010 Oct; 20(7):1132-6. PubMed ID: 21495214
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
[TBL] [Abstract][Full Text] [Related]
36. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Dalton HJ; Fleming ND; Sun CC; Bhosale P; Schmeler KM; Gershenson DM
Gynecol Oncol; 2017 Apr; 145(1):37-40. PubMed ID: 28139261
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract][Full Text] [Related]
38. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
39. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
